4-hydroxymethyl-5-methylfuran-2-carbonitrile | 736183-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 4-hydroxymethyl-5-methylfuran-2-carbonitrile
• 英文别名: 4-Hydroxymethyl-5-methyl-furan-2-carbonitrile；4-(hydroxymethyl)-5-methylfuran-2-carbonitrile
• CAS: 736183-50-9
• 化学式: C₇H₇NO₂
• 分子量: 137.138
• InChiKey: URKQGSKIQGCCJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxymethyl-5-methylfuran-2-carbonitrile 在 哌啶 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 生成 4-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxopyrazolo[3,4-d]pyrimidin-3-yl]-5-methylfuran-2-carbonitrile
  参考文献：
  名称：

  Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: Incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty

  摘要：

  Structure-activity relationships are presented around a series of pyrazolopyrimidinediones that inhibit the growth of Helicobacter pylori by targeting glutamate racemase, an enzyme that provides d-glutamate for the construction of N-acetylglucosamine-N-acetylmuramic acid peptidoglycan subunits assimilated into the bacterial cell wall. Substituents on the inhibitor scaffold were varied to optimize target potency, antibacterial activity and in vivo pharmacokinetic stability. By incorporating an imidazole ring at the 7-position of scaffold, high target potency was achieved due to a hydrogen bonding network that occurs between the 3-position nitrogen atom, a bridging water molecule and the side chains Ser152 and Trp244 of the enzyme. The lipophilicity of the scaffold series proved important for expression of antibacterial activity. Clearances in vitro and in vivo were monitored to identify compounds with improved plasma stability. The basicity of the imidazole may contribute to increased aqueous solubility at lower pH allowing for improved oral bioavailability.

  DOI：

  10.1016/j.bmcl.2012.07.004
• 作为产物：
  描述：

  2-甲基-3-呋喃甲醇 在 氨 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 4-hydroxymethyl-5-methylfuran-2-carbonitrile
  参考文献：
  名称：

  Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: Incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty

  摘要：

  Structure-activity relationships are presented around a series of pyrazolopyrimidinediones that inhibit the growth of Helicobacter pylori by targeting glutamate racemase, an enzyme that provides d-glutamate for the construction of N-acetylglucosamine-N-acetylmuramic acid peptidoglycan subunits assimilated into the bacterial cell wall. Substituents on the inhibitor scaffold were varied to optimize target potency, antibacterial activity and in vivo pharmacokinetic stability. By incorporating an imidazole ring at the 7-position of scaffold, high target potency was achieved due to a hydrogen bonding network that occurs between the 3-position nitrogen atom, a bridging water molecule and the side chains Ser152 and Trp244 of the enzyme. The lipophilicity of the scaffold series proved important for expression of antibacterial activity. Clearances in vitro and in vivo were monitored to identify compounds with improved plasma stability. The basicity of the imidazole may contribute to increased aqueous solubility at lower pH allowing for improved oral bioavailability.

  DOI：

  10.1016/j.bmcl.2012.07.004

文献信息

• [EN] EP4 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES AUX RECEPTEURS EP4
  申请人：PHARMAGENE LAB LTD

  公开号：WO2004067524A1

  公开（公告）日：2004-08-12

  Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl.

  式(I)的化合物：其中：R2为H或可选择地取代的C1-4烷基基团；Y为-(CH2)n-X-，其中n为1或2，X为O、S、S(=O)、S(=O)2或NRN1，其中RN1从H或可选择地取代的C1-4烷基中选择，或Y为-C(=O)NRN2-，其中RN2从H、可选择地取代的C1-7烷基或C5-20芳基中选择；R3为可选择地取代的C6芳基基团，连接到另一个可选择地取代的C6芳基基团，如果两个C6芳基基团均为苯环，则两个环之间可能有氧桥，在两个环上的连接处相邻结合；A为单键或C1-3烷基基团；R5为以下之一：(i)羧基；(ii)式(II)的基团；或(iii)式(III)的基团：其中R为可选择地取代的C1-7烷基、C5-20芳基或NRN3RN4，其中RN3和RN4独立地从可选择地取代的C1-4烷基中选择；(iv)四唑-5-基。
• EP4 receptor antagonists
  申请人：——

  公开号：US20040192767A1

  公开（公告）日：2004-09-30

  Compounds of formula (I): 1 wherein: R 2 is H or an optionally substituted C 1-4 alkyl group; Y is either —(CH 2 ) n —X—, where n is 1 or 2 and X is O, S, S(═O), S(═O) 2 , or NR N1 , where R N1 is selected from H or optionally substituted C 1-4 alkyl, or Y is —C(═O)NR N2 —, where R N2 is selected from H, and optionally substituted C 1-7 alkyl or C 5-20 aryl; R 3 is an optionally substituted C 6 aryl group linked to a further optionally substituted C 6 aryl group, wherein if both C 6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C 1-3 alkylene group; and R 5 is either: (i) carboxy; (ii) a group of formula (II): 2 or (iii) a group of formula (III): 3 wherein R is optionally substituted C 1-7 alkyl, C 5-20 aryl or NR N3 R N4 , where R N3 and R N4 are independently selected from optionally substituted C 1-4 alkyl; (iv) tetrazol-5-yl.

  化学式为(I)的化合物：其中：R2为H或可选取代的C1-4烷基；Y为—（CH2）n—X—，其中n为1或2，X为O，S，S(═O)，S(═O)2，或NRN1，其中RN1选择自H或可选取代的C1-4烷基，或者Y为—C(═O)NRN2—，其中RN2选择自H，可选取代的C1-7烷基或C5-20芳基；R3为可选取代的C6芳基，连接到另一个可选取代的C6芳基，如果两个C6芳基均为苯环，则两个环之间可能有一个氧桥，在两个环上相邻的链接处结合；A为单键或C1-3烷基；R5为：(i)羧基；(ii)化学式为(II)的基团：(iii)化学式为(III)的基团：其中R为可选取代的C1-7烷基，C5-20芳基或NRN3RN4，其中RN3和RN4独立选择自可选取代的C1-4烷基；(iv)四唑-5-基。
• EP4 RECEPTOR ANTAGONISTS
  申请人：Oxford W. Alexander

  公开号：US20070123575A1

  公开（公告）日：2007-05-31

  Compounds of formula (I): wherein: R 2 is H or an optionally substituted C 1-4 alkyl group; Y is either —(CH 2 ) n —X—, where n is 1 or 2 and X is O, S, S(═O), S(═O) 2 , or NR N1 , where R N1 is selected from H or optionally substituted C 1-4 alkyl, or Y is —C(═O)NR N2 —, where R N2 is selected from H, and optionally substituted C 1-7 alkyl or C 5-20 aryl; R 3 is an optionally substituted C 6 aryl group linked to a further optionally substituted C 6 aryl group, wherein if both C 6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C 1-3 alkylene group; and R 5 is either: (i) carboxy; (ii) a group of formula (II): ; or (iii) a group of formula (III): wherein R is optionally substituted C 1-7 alkyl, C 5-20 aryl or NR N3 R N4 , where R N3 and R N4 are independently selected from optionally substituted C 1-4 alkyl; (iv) tetrazol-5-yl.

  式(I)的化合物：其中：R2为H或可选取代的C1-4烷基基团；Y为—(CH2)n—X—或—C(═O)NRN2—，其中n为1或2，X为O、S、S(═O)、S(═O)2或NRN1，其中RN1为选自H或可选取代的C1-4烷基的基团，或Y为—C(═O)NRN2—，其中RN2为选自H、可选取代的C1-7烷基或C5-20芳基基团；R3为可选取代的C6芳基基团，连接到另一个可选取代的C6芳基基团，如果两个C6芳基基团都是苯环，则两个环之间可能有一个氧桥，在两个环上都与连接点相邻；A为单键或C1-3烷基基团；R5为：(i)羧基；(ii)式(II)的基团；或(iii)式(III)的基团；其中R为可选取代的C1-7烷基、C5-20芳基或NRN3RN4，其中RN3和RN4独立选自可选取代的C1-4烷基；(iv)四唑-5-基团。
• US7196089B2
  申请人：——

  公开号：US7196089B2

  公开（公告）日：2007-03-27
• US7507754B2
  申请人：——

  公开号：US7507754B2

  公开（公告）日：2009-03-24